HBJ Report Factory Price - Rs 2500/-
For Payment Options: LINK
After becoming an IT bellwether, India is now shifting its focus to the most promising industry of the future, Biotechnology. With its large pool of scientific talent, world-class information technology industry, and vibrant pharmaceutical sector, India is well positioned to emerge as a significant player in the global biotech arena.
The importance of India in the field of Biotechnology is manifold. In addition to generating trained manpower and a knowledge base, India is proving to be an ideal setting for manufacturing activities and high-level biotechnology research programs. With the initiatives taken by the government, Indian Biotechnology is poised for a tremendous growth. Take for instance the recent boost provided to Research and Development activities. The Union Budget 2010-11 presented by the Finance Minister Mr. Pranab Mukherjee allowed for weighted deduction on expenditure incurred on in-house R&D be enhanced from 150 per cent to 200 per cent. Weighted deduction on payments made to National Laboratories, Research Associations, Colleges, Universities and other institutions for Scientific Research has also been enhanced from 125 per cent to 175 per cent.
India, today, holds a small share of the global biotech market, but has all the capabilities to become a dominant player. As per the study done by the leading institutes the consumption of biotech products in India is expected to quadruple in the next decade. The Indian Biotech industry in 2008–09 clocked US$ 2.67 billion registering a 18 percent growth (in value) over the previous fiscal, while it is expected to touch US$ 5 billion by 2010 and US$ 25 billion by 2015. This kind of growth is phenomenal and definitely unmatched by any other industry.
Till now, we have only had Biocon Ltd in the listed space that has managed to create immense wealth for the shareholders. In Bio-Agri sector, Camson is emulating what Biocon did in Bio -pharma space. However, after an intense research on the Biotechnology as a segment and the operations of the company, we have found a real gem for our "Business Insight - Mar 2010" that is both undervalued and has been an exceptional performer in the past. The research work being carried out by the company, the Patents filed and the expansion of facilities are clearly suggestive of an even brighter future.
As per our research, the "Business Insight" for this month under "Penny stock package" is the best play on the Biotechnology sector and has all the merits to be the leader in its area of operations over a longer period of time.
MPS - Penny stock package
The importance of India in the field of Biotechnology is manifold. In addition to generating trained manpower and a knowledge base, India is proving to be an ideal setting for manufacturing activities and high-level biotechnology research programs. With the initiatives taken by the government, Indian Biotechnology is poised for a tremendous growth. Take for instance the recent boost provided to Research and Development activities. The Union Budget 2010-11 presented by the Finance Minister Mr. Pranab Mukherjee allowed for weighted deduction on expenditure incurred on in-house R&D be enhanced from 150 per cent to 200 per cent. Weighted deduction on payments made to National Laboratories, Research Associations, Colleges, Universities and other institutions for Scientific Research has also been enhanced from 125 per cent to 175 per cent.
India, today, holds a small share of the global biotech market, but has all the capabilities to become a dominant player. As per the study done by the leading institutes the consumption of biotech products in India is expected to quadruple in the next decade. The Indian Biotech industry in 2008–09 clocked US$ 2.67 billion registering a 18 percent growth (in value) over the previous fiscal, while it is expected to touch US$ 5 billion by 2010 and US$ 25 billion by 2015. This kind of growth is phenomenal and definitely unmatched by any other industry.
Till now, we have only had Biocon Ltd in the listed space that has managed to create immense wealth for the shareholders. In Bio-Agri sector, Camson is emulating what Biocon did in Bio -pharma space. However, after an intense research on the Biotechnology as a segment and the operations of the company, we have found a real gem for our "Business Insight - Mar 2010" that is both undervalued and has been an exceptional performer in the past. The research work being carried out by the company, the Patents filed and the expansion of facilities are clearly suggestive of an even brighter future.
As per our research, the "Business Insight" for this month under "Penny stock package" is the best play on the Biotechnology sector and has all the merits to be the leader in its area of operations over a longer period of time.
MPS - Penny stock package
